Amgen's Imlygic gets EU committee backing; Merck touts Keytruda survival data in NSCLC;

> Amgen ($AMGN) nabbed European backing for a first-in-class cancer treatment, Imlygic, that uses a virus to deliver immunotherapy; the drug is on its way to FDA approval in the U.S. Report

> Merck & Co. ($MRK) touted top-line data showing that its immuno-oncology drug Keytruda helped certain patients with non-small-cell lung cancer live longer. Release

> GlaxoSmithKline ($GSK) won European backing to expand approval of Volibris, a treatment for pulmonary arterial hypertension, to use in combination with other meds. Report

> Novartis' ($NVS) psoriasis med Cosentyx got a thumbs up from Europe's drug approval committee for new uses in ankylosing spondylitis and psoriatic arthritis. Report

> Rare disease specialist Alexion Pharmaceuticals ($ALXN) nabbed an FDA clearance for Strensiq, which treats hypophosphatasia, a genetic disorder. Release | Report

And Finally... A new report linked some types of cancer with consumption of processed meat such as bacon and hot dogs. Report